

Poolbeg Pharma announces expansion of POLB 001 into oncology



NEWS RELEASE BY POOLBEG PHARMA PLC

London, UK | January 18, 2023 08:10 AM Eastern Standard Time

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Proactive's Thomas Warner after announcing that the company has submitted a patent application for the use of POLB 001 in a new oncological indication. Skillington explains the reasons for the strategic expansion and reveals more about his vision for the molecule in the long term.



Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com

Tags

HEALTH

PHARMA & BIOTECH

ONCOLOGY

CANCER